Logo image of CDTX

CIDARA THERAPEUTICS INC (CDTX) Stock Fundamental Analysis

NASDAQ:CDTX - Nasdaq - US1717572069 - Common Stock - Currency: USD

21.54  -0.84 (-3.75%)

Fundamental Rating

2

Overall CDTX gets a fundamental rating of 2 out of 10. We evaluated CDTX against 572 industry peers in the Biotechnology industry. CDTX may be in some trouble as it scores bad on both profitability and health. CDTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CDTX has reported negative net income.
CDTX had a negative operating cash flow in the past year.
CDTX had negative earnings in each of the past 5 years.
CDTX had a negative operating cash flow in each of the past 5 years.
CDTX Yearly Net Income VS EBIT VS OCF VS FCFCDTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -75.85%, CDTX is not doing good in the industry: 67.67% of the companies in the same industry are doing better.
CDTX's Return On Equity of -106.49% is in line compared to the rest of the industry. CDTX outperforms 44.41% of its industry peers.
Industry RankSector Rank
ROA -75.85%
ROE -106.49%
ROIC N/A
ROA(3y)-53.77%
ROA(5y)-68.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CDTX Yearly ROA, ROE, ROICCDTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1K 2K 3K 4K

1.3 Margins

CDTX's Gross Margin of 236.76% is amongst the best of the industry. CDTX outperforms 99.82% of its industry peers.
The Profit Margin and Operating Margin are not available for CDTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 236.76%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CDTX Yearly Profit, Operating, Gross MarginsCDTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600

More info and screens

3

2. Health

2.1 Basic Checks

CDTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CDTX has been increased compared to 1 year ago.
Compared to 5 years ago, CDTX has more shares outstanding
CDTX has a worse debt/assets ratio than last year.
CDTX Yearly Shares OutstandingCDTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
CDTX Yearly Total Debt VS Total AssetsCDTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

CDTX has an Altman-Z score of -1.60. This is a bad value and indicates that CDTX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CDTX (-1.60) is comparable to the rest of the industry.
CDTX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.00, CDTX is in line with its industry, outperforming 46.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.6
ROIC/WACCN/A
WACC9.44%
CDTX Yearly LT Debt VS Equity VS FCFCDTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 3.54 indicates that CDTX has no problem at all paying its short term obligations.
CDTX's Current ratio of 3.54 is in line compared to the rest of the industry. CDTX outperforms 41.92% of its industry peers.
A Quick Ratio of 3.54 indicates that CDTX has no problem at all paying its short term obligations.
CDTX's Quick ratio of 3.54 is in line compared to the rest of the industry. CDTX outperforms 43.16% of its industry peers.
Industry RankSector Rank
Current Ratio 3.54
Quick Ratio 3.54
CDTX Yearly Current Assets VS Current LiabilitesCDTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 11.28% over the past year.
CDTX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -53.63%.
CDTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 74.31% yearly.
EPS 1Y (TTM)11.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.11%
Revenue 1Y (TTM)-53.63%
Revenue growth 3Y74.31%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 2.40% on average over the next years.
The Revenue is expected to decrease by -2.90% on average over the next years.
EPS Next Y-413.51%
EPS Next 2Y-42.73%
EPS Next 3Y-26.37%
EPS Next 5Y2.4%
Revenue Next Year-88.09%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-2.9%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CDTX Yearly Revenue VS EstimatesCDTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
CDTX Yearly EPS VS EstimatesCDTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CDTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CDTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CDTX Price Earnings VS Forward Price EarningsCDTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CDTX Per share dataCDTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

CDTX's earnings are expected to decrease with -26.37% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-42.73%
EPS Next 3Y-26.37%

More info and screens

0

5. Dividend

5.1 Amount

CDTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CIDARA THERAPEUTICS INC

NASDAQ:CDTX (2/21/2025, 8:06:49 PM)

21.54

-0.84 (-3.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)04-21 2025-04-21/amc
Inst Owners70.5%
Inst Owner Change88.6%
Ins Owners0.71%
Ins Owner Change-0.02%
Market Cap235.86M
Analysts85
Price Target34.88 (61.93%)
Short Float %1.28%
Short Ratio1.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)50.61%
Min EPS beat(2)43.48%
Max EPS beat(2)57.74%
EPS beat(4)3
Avg EPS beat(4)-213.59%
Min EPS beat(4)-1017.65%
Max EPS beat(4)62.05%
EPS beat(8)5
Avg EPS beat(8)-80.66%
EPS beat(12)8
Avg EPS beat(12)-48.6%
EPS beat(16)9
Avg EPS beat(16)-26.57%
Revenue beat(2)0
Avg Revenue beat(2)-96.85%
Min Revenue beat(2)-100%
Max Revenue beat(2)-93.7%
Revenue beat(4)2
Avg Revenue beat(4)-28.16%
Min Revenue beat(4)-100%
Max Revenue beat(4)49.35%
Revenue beat(8)4
Avg Revenue beat(8)-7.77%
Revenue beat(12)7
Avg Revenue beat(12)2.2%
Revenue beat(16)9
Avg Revenue beat(16)6.09%
PT rev (1m)6.21%
PT rev (3m)15.28%
EPS NQ rev (1m)2.23%
EPS NQ rev (3m)37.59%
EPS NY rev (1m)1.09%
EPS NY rev (3m)7.02%
Revenue NQ rev (1m)-20%
Revenue NQ rev (3m)-95.86%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-31.09%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.95
P/FCF N/A
P/OCF N/A
P/B 2.04
P/tB 2.04
EV/EBITDA N/A
EPS(TTM)-6.92
EYN/A
EPS(NY)-9.78
Fwd EYN/A
FCF(TTM)-14.63
FCFYN/A
OCF(TTM)-14.6
OCFYN/A
SpS2.41
BVpS10.56
TBVpS10.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -75.85%
ROE -106.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 236.76%
FCFM N/A
ROA(3y)-53.77%
ROA(5y)-68.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 144.13%
Cap/Sales 1.17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.54
Quick Ratio 3.54
Altman-Z -1.6
F-Score2
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)177.39%
Cap/Depr(5y)121.58%
Cap/Sales(3y)0.35%
Cap/Sales(5y)0.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.11%
EPS Next Y-413.51%
EPS Next 2Y-42.73%
EPS Next 3Y-26.37%
EPS Next 5Y2.4%
Revenue 1Y (TTM)-53.63%
Revenue growth 3Y74.31%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-88.09%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-2.9%
EBIT growth 1Y-26.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-612.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-614.28%
OCF growth 3YN/A
OCF growth 5YN/A